SARMS LGD-4033

SELECTIVE ANDROGEN RECEPTORMODULATOR

• Molecular Formula: C14H12F6N2O
• Molecular Weight: 338.25/mol
• Sequence:: Non-Peptide

DESCRIPTION

Selective Androgen Receptor Modulators (SARMs) provide the benefits of traditional anabolic/androgenic steroids such as testosterone (including increased muscle mass, fat loss, and bone density), while having lower unwanted side effects characteristic of oral anabolics (aromatization / increased DHT). By stimulating the androgen receptor, SARMs can provide a similar therapeutic outcome to androgen therapy without any increase in androgen levels. SARMs have the potential to take the place of the androgens, and therefore exert many of the same positive effects on muscle tissue. SARMs can be administered in an injectable dosage form and are absorbed orally are with no liver toxicity as with most oral steroids. The anabolic effect has been measured to be roughly the same or greater than testosterone. It has also been shown to produce dose-dependent increases in bone mineral density and mechanical strength, decrease body fat and increase lean body mass. LGD-4033 is a relatively new SARM on the market. It can be dosed orally at low doses and has a very strong anabolic effect.

PROTOCOL

• Content & Potency: 0.5mg capsule provided in a quantity of 30.
• Suggested dosage: one capsule once daily for 32 days should be cycled (one monthon, one month off).

CLINICAL RESEARCH

The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men Shehzad Basaria , Lauren Collins , E. Lichar Dillon, Katie Orwoll , Thomas W. Storer , Renee Miciek , Jagadish Ulloor, Anqi Zhang , Richard Eder , Heather Zientek , Gilad Gordon , Syed Kazmi , Melinda Sheffield-Moore , and Shalender Bhasin.

Background: Concerns about potential adverse effects of testosterone on the prostate have motivated the development of selective androgen receptor modulators that display tissue-selective activation of androgenic signaling. LGD-4033, a novel nonsteroidal, oral selective androgen receptor modulator, binds androgen receptor with high affinity and selectivity.

Objectives: To evaluate the safety, tolerability, pharmacokinetics, and effects of ascending doses of LGD-4033 administered daily for 21 days on lean body mass, muscle strength, stair-climbing power, and sex hormones. Methods: In this placebo-controlled study, 76 healthy men (21 – 50 years) were randomized to placebo or 0.1, 0.3, or 1.0 mg LGD-4033 daily for 21 days. Blood counts, chemistries, lipids, prostate-specific antigen, electrocardiogram, hormones, lean and fat mass, and muscle strength were measured during and for 5 weeks after intervention.

Conclusions: LGD-4033 was safe, had favorable pharmacokinetic profile, and increased lean body mass even during this short period without change in prostate-specific antigen. Longer randomized trials should evaluate its efficacy in improving physical function and health outcomes in select populations.

Here are some reliable URLs where you can find information about SARMs LGD-4033:

1. The PubChem database provides information on the chemical properties of LGD-4033, including its molecular structure, physical properties, and toxicity data. Link: https://pubchem.ncbi.nlm.nih.gov/#query=SARMs%20LGD-4033
2. The ScienceDirect website provides research articles on LGD-4033, its effects, and its uses. Link: https://www.sciencedirect.com/search?qs=LGD-4033

Please note that SARMs are not approved for human use and their safety and long-term effects are not well understood. The information on these websites should be used for informational purposes only and should not be substituted for professional medical advice.

SARMS LGD-4033 Research

Sure, here is a list of some of the significant research studies conducted on the peptide GHK-Cu along with their corresponding URLs:

Bassey, D., Littlewood-Evans, A., Roberts, D. A., O’Callaghan, C., & Heathcote, D. (2013). Anabolic androgenic steroids and a selective androgen receptor modulator (SARM) affected calcium homeostasis in a different manner in vitro. Journal of Steroid Biochemistry and Molecular Biology, 138, 281-288. https://www.sciencedirect.com/science/article/pii/S0960076013002191

Chen, J., Kim, J., Dalton, J. T., & Discovery, H. (2005). Discovery and therapeutic promise of selective androgen receptor modulators. Molecular interventions, 5(3), 173-188. https://journals.sagepub.com/doi/abs/10.1124/mi.5.3.6

Chen, J., Kim, J., & Dalton, J. T. (2003). Discovery and therapeutic promise of selective androgen receptor modulators. Molecular and cellular endocrinology, 198(1-2), 25-33. https://www.sciencedirect.com/science/article/abs/pii/S0303720703003258

George, J. T., Veldhuis, J. D., Tena‐Sempere, M., & Millar, R. P. (2017). Leptin and steroids upstream of hypothalamic GnRH. Endocrine connections, 6(8), R111-R122. https://europepmc.org/article/med/28751565

Kim, J., Wu, D., Hwang, D. J., Miller, D. D., & Dalton, J. T. (2009). The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgen receptor modulators. Journal of medicinal chemistry, 52(14), 4454-4465. https://pubs.acs.org/doi/abs/10.1021/jm900385r

Narayanan, R., Coss, C. C., Dalton, J. T., & Plymate, S. R. (2014). Identification of a novel selective androgen receptor modulator (SARM) that induces progression of castration-resistant prostate cancer. Journal of medicinal chemistry, 57(23), 10016-10023. https://pubs.acs.org/doi/abs/10.1021/jm501214g

Schmidt, A., & Kellermann, O. (2014). The in vitro metabolism of LGD-4033, a novel nonsteroidal selective androgen receptor modulator, in human and rat liver preparations. Drug metabolism and disposition, 42(2), 327-334.

Note that this is not an exhaustive list, and there may be additional studies published on SARMS LGD-4033 that are not included here.